Clinical Trials

165 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07061977 2026-05-26

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Phase 3 Recruiting

336 enrolled

Phase 2 Not yet recruiting

Locally Advanced Cervical Adenocarcinoma

NCT07495124 2026-05-26

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

26 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04633239 2026-05-22

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Phase 1 Recruiting

42 enrolled

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT03367741 2026-05-19

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

82 enrolled 11 charts

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT07001748 2026-05-15

STOPGAP II

Phase 2/3 Recruiting

148 enrolled

Peritoneal Neoplasms

NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

59 enrolled

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT02834013 2026-05-13

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

818 enrolled

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT04092270 2026-05-13

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

54 enrolled

Phase EARLY_PHASE1 Active not recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

12 enrolled

Endometrial Serous Adenocarcinoma

NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

BreastGastrointestinalGenitourinaryGynecologic

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

BreastGastrointestinalGynecologicHead & NeckSarcoma

51 enrolled

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04840589 2026-05-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Phase 1 Suspended

66 enrolled

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Ovarian Neoplasms

NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

96 enrolled

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

NCT05554367 2026-05-13

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

GastrointestinalGynecologic

199 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms

NCT05691504 2026-05-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Phase NA Active not recruiting

42 enrolled

GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

NCT06498661 2026-05-13

SHIP-A-S01

750 enrolled

Phase NA Active not recruiting

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT06611540 2026-05-13

LMI-001-A-S03

500 enrolled

Phase NA Active not recruiting

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT06611553 2026-05-13

LMI-001-A-S02

500 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT06995898 2026-05-13

The Vanguard Study: Testing a New Way to Screen for Cancer

Phase NA Recruiting

24,000 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07281430 2026-05-13

LMI-001-A-S04

Phase NA Recruiting

500 enrolled

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT07504588 2026-05-13

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

87 enrolled

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT05950464 2026-05-11

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Phase 1 Recruiting

65 enrolled

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

50 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Phase 1/2 Recruiting

147 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

NCT01116648 2026-05-04

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Phase 1/2 Active not recruiting

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT02446600 2026-05-04

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02345265 2026-04-30

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

70 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02595879 2026-04-29

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

21 enrolled 22 charts

Uterine Cervical Neoplasms

NCT05112601 2026-04-21

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

81 enrolled

Endometrial Neoplasms, Carcinoma, Endometrioid

NCT07407647 2026-04-21

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

GastrointestinalGynecologic

25 enrolled

Anus Neoplasms, Uterine Cervical Neoplasms, Rectal Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT04034927 2026-04-13

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

61 enrolled 15 charts

Fallopian Tube Neoplasms

NCT04739800 2026-04-13

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

120 enrolled 19 charts

GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT05920798 2026-04-06

FRAPPE

Phase 1/2 Recruiting

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06915727 2026-04-01

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

Phase 3 Recruiting

20 enrolled

GynecologicHead & Neck

Head and Neck Neoplasms, Pelvic Neoplasms

NCT04251052 2026-03-27

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Phase NA Recruiting

1,956 enrolled

Ovarian Neoplasms

NCT07276360 2026-03-27

HypoRTCx-UG

278 enrolled

Phase 3 Active not recruiting

Uterine Cervical Neoplasms

NCT04095364 2026-03-24

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

450 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06580314 2026-03-24

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Phase 3 Recruiting

880 enrolled

Ovarian Neoplasms

NCT04514484 2026-03-23

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

8 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06483048 2026-03-16

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Phase 1 Recruiting

12 enrolled